Mesoridazine's classification as an antipsychotic means it falls under which category?

Mesoridazine is classified as a first-generation antipsychotic, also known as a typical antipsychotic. This classification is based on its pharmacological properties and the era in which it was developed, linking it to the original class of antipsychotic medications that focus primarily on dopamine receptor antagonism in the treatment of psychotic disorders, such as schizophrenia.

First-generation antipsychotics are known to be effective in managing positive symptoms of schizophrenia, such as hallucinations and delusions, largely due to their strong dopamine D2 receptor antagonism. Mesoridazine, like other first-generation agents, is associated with a higher risk of extrapyramidal symptoms due to its dopamine-blocking effects.

In contrast, second-generation antipsychotics (also known as atypical antipsychotics) have a broader mechanism of action and are known for their reduced risk of extrapyramidal symptoms, largely due to their effects on both dopamine and serotonin receptors. SSRIs (Selective Serotonin Reuptake Inhibitors) and tricyclic antidepressants are classes of antidepressants and do not fall under the antipsychotic category; these medications target different neurotransmitter systems to address mood disorders rather than psychosis.